A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE)

More than half of the patients with head and neck squamous cell carcinomas (HNSCC) are diagnosed at a locally advanced stage (LA) [1]. The standard of care for LAHNSCC treatment is concurrent chemoradiation with curative intent. Although this locoregionally targeted therapy is effective in the majority of patients, locoregional recurrences are four-fold more common than metastases [2].

Source: Radiotherapy and Oncology - April 16, 2024 Category: Radiology Authors: Anna Liza M.P. de Leeuw, Jordi Giralt, Yungan Tao, Sergi Benavente, Thanh-V ân France Nguyen, Frank J.P. Hoebers, Ann Hoeben, Chris H.J. Terhaard, Lip Wai Lee, Signe Friesland, Roel J.H.M. Steenbakkers, Lisa Tans, Jolien Heukelom, Mutamba T. Kayembe, Sim Tags: Original Article Source Type: research